Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications (Q36433583)

14 August 2017

1 reference

title

Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications (English)

1 reference

14 August 2017

0 references

1 reference

1 reference

Samuel Lévy

1

1 reference

14 August 2017

publication date

1 April 2006

1 reference

Nature Clinical Practice Cardiovascular Medicine

14 August 2017

published in

1 reference

14 August 2017

volume

3

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

220-225

1 reference

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Socie

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Angiotensin II, platelets and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Angiotensin-converting enzyme 2--a new cardiac regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

A multicenter risk index for atrial fibrillation after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Myocardial cell death in fibrillating and dilated human right atria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Myocardial fibrosis: functional significance and regulatory factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Renin-angiotensin system gene polymorphisms and atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Role of angiotensin-converting enzyme inhibitors in the prevention of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

Tolerability of enalapril in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

7 January 2021

Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

7 January 2021

Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

7 January 2021

Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

7 January 2021

Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

7 January 2021

Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0480

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO0480

1 reference

Dimensions Publication ID

14 August 2017

1000663370

0 references

1 reference